Apollo Biowellness, Inc., Corporate Status and Merger Update

About this update from Resonate Blends Inc.

Apollo Biowellness, Inc., Corporate Status and Merger Update Apollo Biowellness, Inc., Corporate Status and Merger Update Newsfile Corp. Newsfile Corp North Bergen, New Jersey--(Newsfile Corp. - October 29, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to announce it is updating its shareholders on various developments and updates on both corporate developments and an update on the merger with Revive Regenerative, Inc. The Company will continue to update and will provide more information and greater detail over the next few weeks. In the future, we will have an update and status on the consumer based biologic cosmetic product, called Cielo Skin Care, as we are finalizing our partnership with our Israeli based biologic manufacturing company. We have completed the initial bridge financing for the merger with Revive Regenerative, Inc., and we are actively negotiating, in conjunction with our financial advisory firm, with all the Company's creditors and debtors, for the conversion of all debt in the Company to equity which is an agreed upon condition of closing for the transaction with Revive Regenerative, Inc. The original closing date for the merger/transaction was October 30, 2025, but our investment banking firm and advisor is informing us that while it is making great headway, approximately another 30 days is needed to complete the process. In addition, the Company is working with various investors on the additional $3,000,000 raise (in addition to the initial $500,000 bridge financing) needed as per the Merger Agreement. Both parties have cooperated in due diligence and are very satisfied with the integration of the two companies and both sides agree to close upon the satisfactory resolution of the debt, as stated above, and both sides are anxious to close as soon as possible. The Company is also in negotiations with a tele-med GPL-1 Peptide company that can provide a full line of GLP-1 products, along with various peptides, to be sold in conjunction with our current line of biologics. A more definitive update on the conversion of debt is expected to be known in the next 7 to 10 days and will be released as soon as the information is available, and both sides are eager to close the merger transaction as soon as possible, once this conversion is completed. To view an enhanced version of this graphic, please visit: https://ima...

View stock analysis, news, and events for Resonate Blends Inc.